BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24169086)

  • 21. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.
    Nemec P; Zemanova Z; Greslikova H; Michalova K; Filkova H; Tajtlova J; Kralova D; Kupska R; Smetana J; Krejci M; Pour L; Zahradova L; Sandecka V; Adam Z; Buchler T; Spicka I; Gregora E; Kuglik P; Hajek R
    Biol Blood Marrow Transplant; 2010 Apr; 16(4):548-54. PubMed ID: 20005965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
    Chang H; Trieu Y; Qi X; Xu W; Stewart KA; Reece D
    Leuk Res; 2007 Jun; 31(6):779-82. PubMed ID: 16996589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization are complementary techniques to detect cytogenetic abnormalities in multiple myeloma.
    Alpar D; de Jong D; Holczer-Nagy Z; Kajtar B; Savola S; Jakso P; David M; Kosztolanyi S; Kereskai L; Pajor L; Szuhai K
    Genes Chromosomes Cancer; 2013 Sep; 52(9):785-93. PubMed ID: 23720363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma.
    Chang H; Jiang N; Jiang H; Saha MN; Qi C; Xu W; Reece D
    Haematologica; 2010 Sep; 95(9):1542-7. PubMed ID: 20421271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.
    Rasillo A; Tabernero MD; Sánchez ML; Pérez de Andrés M; Martín Ayuso M; Hernández J; Moro MJ; Fernández-Calvo J; Sayagués JM; Bortoluci A; San Miguel JF; Orfao A
    Cancer; 2003 Feb; 97(3):601-9. PubMed ID: 12548602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Fluorescence in situ hybridization identifies complex chromosomal aberrations in multiple myeloma].
    Liu SY; Huang JW; Zhang J; Du HP; Jiang H; Li JY; Xue YQ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Dec; 24(6):685-8. PubMed ID: 18067084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens.
    Grzasko N; Hus M; Chocholska S; Pluta A; Hajek R; Dmoszynska A
    Leuk Lymphoma; 2012 Dec; 53(12):2500-3. PubMed ID: 22497640
    [No Abstract]   [Full Text] [Related]  

  • 28. A retrospective analysis of cytogenetic and clinical characteristics in patients with multiple myeloma.
    He J; Yang L; Meng X; Wei G; Wu W; Han X; Zheng G; Zheng W; Ye X; Shi J; Xie W; Zhang J; Huang H; Lin M; Cai Z
    Am J Med Sci; 2013 Feb; 345(2):88-93. PubMed ID: 22986611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Correlation between chromosome 13q14 deletion and 1q abnormality in multiple myeloma].
    Chen LJ; Li JY; Zhu Y; Wang XW; Qiu HR; Yang RF; Xu W; Xu JR; Lu H
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Feb; 26(1):102-5. PubMed ID: 19199264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Detection of chromosomal aberrations in multiple myeloma with fluorescence in situ hybridization].
    Cao P; Chen F; Cheng Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 37(10):983-9. PubMed ID: 23117450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Study on molecular cytogenetic abnormalities in multiple myeloma].
    Liu SY; Li JY; Chen LJ; Huang JW; Pan JL; Qiu HR; Shen YF; Xu W; Xue YQ
    Zhonghua Xue Ye Xue Za Zhi; 2007 Apr; 28(4):223-6. PubMed ID: 17877196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chromosome 1 abnormalities in multiple myeloma.
    Marzin Y; Jamet D; Douet-Guilbert N; Morel F; Le Bris MJ; Morice P; Abgrall JF; Berthou C; De Braekeleer M
    Anticancer Res; 2006; 26(2A):953-9. PubMed ID: 16619492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular cytogenetic aberrations in Tunisian patients with multiple myeloma identified by cIg-FISH in fixed bone marrow cells.
    Gmidène A; Avet-Loiseau H; Sennana H; Ben Abdallah I; Khlif A; Meddeb B; Elloumi M; Saad A
    Cytogenet Genome Res; 2012; 136(1):44-9. PubMed ID: 22188899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation.
    Chang H; Yeung J; Xu W; Ning Y; Patterson B
    Br J Haematol; 2006 Sep; 134(6):613-5. PubMed ID: 16889615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Frequency and prognostic value of chromosome abnormalities in multiple myeloma].
    Kurahashi S; Sawamoto A; Sugimoto T; Narimatsu H; Iwasaki T; Adachi T; Suzuki H; Hayakawa F; Sugiura I
    Rinsho Ketsueki; 2007 Nov; 48(11):1455-61. PubMed ID: 18080502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Wu KL; Beverloo B; Lokhorst HM; Segeren CM; van der Holt B; Steijaert MM; Westveer PH; Poddighe PJ; Verhoef GE; Sonneveld P; ;
    Br J Haematol; 2007 Feb; 136(4):615-23. PubMed ID: 17223915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance.
    Schmidt-Wolf IG; Glasmacher A; Hahn-Ast C; Jüttner A; Schnurr T; Cremer F; Moehler T; Goldschmidt H; Busert B; Schubert R; Schwanitz G
    Cancer Genet Cytogenet; 2006 May; 167(1):20-5. PubMed ID: 16682281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype/genotype fluorescence in situ hybridization.
    Slovak ML; Bedell V; Pagel K; Chang KL; Smith D; Somlo G
    Cancer Genet Cytogenet; 2005 Apr; 158(2):99-109. PubMed ID: 15796956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
    Sawyer JR
    Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Molecular genetic methods for the prognostic criteria in multiple myeloma].
    Mikala G; Jákó J; Vályi-Nagy I
    Orv Hetil; 2005 Aug; 146(32):1673-82. PubMed ID: 16149245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.